Takeda Put Actos Sales Ahead of User Safety, Witness Says

Takeda Pharmaceutical Co., Asia’s biggest drugmaker, put sales of its Actos diabetes drug ahead of concerns about consumer safety, a witness testified in the first trial over claims the medicine caused cancer.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.